Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like all the specials are out today.
Mental games are played with bio's this size. If we happen to close in the High 70's low 80's lots of blue birds will fly away once again.
Raid !
Wookster, is that you doing all the buying again today ? At least we know its in good claws.
Go North
D
I'll give you a list however you'll have to help me a bit. I'm not so savvy with the computer. (It's an age thing I guess , anyhow). If you go back to find one of I believe Biopharms lists of potential events that will possibly occur in the immediate future than you have not only cherry picked but you'll find an entire grove of cherry trees that are ready for pick'n......
ENJOY ! Hope this helps
D
Zare. All of a sudden the scene from Animal House comes to mind. I'm sure some might recall when Belushi in the (frat house) rallied the guys to rebel against closing there house I believe....,.. Anyway, I'm with you Zare however, the timing is the difficult part to figure. From a logical perspective why and how can a BP let this little company just walk on its own ? IMO it's like a three ring circus at PPHM and all eyes are starting to open to the potential ..... I don't think any long will have much to decide because at some point we will be bought by a BP.
Gltua
Dave
How do you know they aren't going to do anything with it ? I guess you spoke with someone at the company ? Is this an assumption ? Please support your statement if you can. I know I've opened the door for you to criticize the company but maybe there is something I missed.
Btw the last post that you made to me is that you were going to follow the pps because of something I stated. Just wanted an update on how I'm doing. Tia
I recall that you opinionated that a deal was basically complete. I agree with you that most of the detail is already worked out. The sensitivity of conviction only matters with the credibility of the poster here on this board. At the end of the day we know that the risk reward is why most longs are here. I like the odds that you and I are correct. We shall see soon enough.
D
I'm betting we are below 7m
Unless they short against the box ....need eye on this.
Me thinks you woke up the board. I agree the ink is still drying however, until we run a bit more we will not know who.
D
Share based compensation is for the current taxable year. (6 months worth). The meaning is, comparison of the increase of $ compared to the same period of the prior period. All things being equal from year to year...it's an increase in expense due to activity. I do not believe that Cotara is still on the shelf completely. If your in the camp that believes that we are in partnership talks than the entire closet has to be viewed by the suitor. All is on the table for viewing.
All IMO
D
Sorry !
Not sure when this will be updated:
Peregrine Pharmaceuticals Incorporated
$ 1.81
PPHM
-0.10
Daily Short Sale Volume
view
Short Interest (Shares Short)
8,478,500
Days To Cover (Short Interest Ratio)
6.1
Short Percent of Float
5.60 %
Short Interest - Prior
8,661,600
Short % Increase / Decrease
-2.11
Daily Naked Short Selling List
view
Short Squeeze Rankingâ„¢
view
% From 52-Wk High ($ 2.43 )
-25.51%
% From 52-Wk Low ($ 1.11 )
63.06%
% From 200-Day MA ($ 1.44 )
25.49%
% From 50-Day MA ($ 1.44 )
25.59%
Price % Change (52-Week)
-12.56%
Shares Float
151,330,000
% Owned by Insiders
6.95%
% Owned by Institutions
8.20%
Market Cap.
$ 290,000,000
Trading Volume - Today
5,515,481
Trading Volume - Average
1,385,300
Trading Volume - Today vs. Average
398.14%
Earnings Per Share
-0.20
PE Ratio
0.00
Record Date
2014-JanA
Sector
Industry
Exchange
NAS
Just a reminder -
Jan 30, 2014 GTC Novel Immunotherapeutics Summit 2014
Speaker: Bruce Freimark, PhD, Phosphatidylserine Targeting Antibodies Enhances Activity of Immune Checkpoint Inhibitors and Re-activates Immune System in Tumors
Phosphatidylserine (PS) is a phospholipid normally residing in the inner leaflet of the plasma membrane and becomes exposed on tumor vascular endothelial cells (ECs) and tumor cells. PS exposure becomes enhanced in response to chemotherapy, irradiation, and oxidative stresses in the tumor microenvironment. PS exposure in tumors promotes an immunosuppressive microenvironment which includes the recruitment of myeloid derived suppressor cells, immature dendritic cells, and M2-like tumor associated macrophages as well as the production of anti-inflammatory cytokines. Bavituximab, a chimeric PS-targeting antibody, is being used in combination with chemotherapy to treat patients with solid tumors in multiple late-stage clinical trials. Binding of PS targeting antibodies on tumor ECs, tumor cells and their secreted microparticles increase the presence of M1-like macrophages and cytokine responses that reverse the immunosuppressive PS mediated checkpoint, thereby enhancing anti-tumor immunity. Using multiple tumor models in mice, we demonstrate PS targeting antibodies enhance the anti-tumor activity of multiple forms of therapy including anti-CTLA-4 and anti-PD-1 checkpoint inhibitor antibodies. Tumor growth inhibition correlates with infiltration of immune cells in tumors and induction of adaptive immunity. The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation.
Feb 25–26, 2014 RBC Capital Markets Healthcare Conference
Location: New York Palace Hotel New York, New York
Mar 3–5, 2014 Cowen & Co. 34th Annual Health Care Conference
Location: Boston Marriott Copley Place Boston, Mass.
Mar 9–12, 2014 26th Annual ROTH Conference
Location: The Ritz-Carlton Dana Point, California
3:59 PM ET 1/24/14 | Marketwire
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc., today announced that recent studies demonstrated that it is possible to control key product quality attributes through cell culture conditions. Using Design of Experiments (DoE), the cell culture conditions within the process design space were identified during process understanding and modeling studies that allowed for the control or manipulation of afucosylation (G0) levels. This case study will be presented at the Well Characterized Biotechnology Pharmaceutical (WCBP) 18th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products, to be held in Washington, DC, January 27-30, 2014.
Glycosylation is a common posttranslational modification that has shown to be a critical quality attribute (CQA) of recombinant monoclonal antibodies. In particular, the level of afucosylation (for example, G0) is a key glycosylation parameter associated with enhanced antibody activity, for a monoclonal antibody in clinical development.
"By applying a Quality by Design (QbD) approach, we gained a greater insight into how to better control the process, as well as the creation of a clearer blueprint for future development in order to increase our efficiency and, in the end, deliver a more robust process to our clients," said Connie Chang, director of process sciences for Avid Bioservices. "The control of glycosylation and particularly afucosylation is challenging and these results are an important development for this monoclonal antibody. The results from our recent studies show that two Critical Process Parameters significantly affect the afucosylation levels on the antibody. This understanding enabled process modifications within the design space to increase the G0 levels for an existing client cell line. In addition, the increased understanding of process parameters has allowed us to identify additional process controls that allow for more consistent CQAs from batch to batch."
Poster Presentation Details:
Title: "Characterization of Bioreactor Conditions Effect on Afucosylation" Date: Wednesday, January 29, 2014 Time: 3:15 - 4:15 P.M. EST Location: Poster Board # P-226-W Authors: Vince Nguyen, Michael Brown, Roy Sevilla, Aditi Iyengar, Gary Larson, Karyn Pinson, Payam Farahani, Michael Wang, Calla Montelongo, Olegario Garcia, Mary Wakabayashi, Mary Knauer, Connie Chang
In addition, Avid Bioservices will be hosting conference attendees at booth #19 in the exhibit hall.
For additional information on the WCBP 18th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products, please visit: https://m360.casss.org/event.aspx?eventID=72301
About Avid Bioservices Avid Bioservices provides a comprehensive range of high quality cGMP manufacturing services for the biotechnology and biopharmaceutical industries to support the manufacture of cGMP clinical phase and commercial products. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include GMP clinical and commercial product manufacturing, purification, bulk packaging, final product filling, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab while seeking a partner to further advance its novel brain cancer agent Cotara(R). Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Contact:
Chris Keenan or Kelly Pisarev Lord
(800) 987-8256
www.avidbio.com
Chenzo. Just takes a little getting used to in the NE.
Enjoy the weekend !
D
Nice post.
I'm sure CP can confirm L3 as well.
L2 looks pretty calm even past $1.85.
4mil. Nice accumulation.
I think monster is correct. $1.84 or so at the close.
D
I would really like to trade over $2 today and see it hold going into next week. After all this is pphm.
Going North.
Glta
D
We lost gods gift in Dr. T but he left us with a science that will impact the world of cancer. It's in good hands with Dr. B and this company will take it over all hurdles and be victorious.
We will prevail IMO.
D
Nope. 3700 shares bid at $1.86 more important is the offer of $1.99. No ones running.
Tradero I agree with you summation. Secondly, I don't see any relationship with the science. Heck look at Msft and appl as both CEO's left for circumstances. IMO this is not an event that will impede the progress of Bavi.
GN
D
Ps. Thank you Gwen.
Sir Jim. I wish you strength.
Dave
Bio. Would you consider this a non-event, good or bad ?
Tx
Talk about history repeating. Wow.
Going North
D
It's all about manipulation. You think those millions of shares bought yesterday are gonna win ? I do. I know you do to.
Hang in there Rev. The party ain't over yet.
I see this as accumulation of weak hands and profit taking from the 6 months or so trading around $1.40. I believe the new hands are more than just retail and we can build from here.
D
Looks healthy to me. I can see the chart now. Just as the Wookster said. A nice V.... So the next time we break $2 it keep on go'n..
All IMO of course.
D
Can we see a close over $ 2 today ??
How sweet that would be !
D
Stone. I agree.
It's gotta hold it ! Used sme powder at .92.
D
2.5 million traded. Lots of buys !
We will trade above $2 again real soon. Maybe not today but it will happen real soon.
D
CP. I have the euro at 1.3634, just a tad higher which puts us at $2.10.
I would hope that the shares that traded pre market on Tuesday @ $2.20 turn green today.
GN
D
IMO there are capital asset managers and institutions that would love to buy in on pphm at this point however, price restriction won't allow them. As we climb in prices more funds will buy in. (100m ?)
Go N-----
D
It's about time Bio. Jeeez, I've been waiting days for your update. (Lol). Thank you.
D
Thanks Eye
D
Wookster
Slip of the thought I guess. Maybe it comes true sooner than later about publicity. CNN , cnbc , fox....etc...
Go N-----
D